Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 538 participants.

Also called NCT07476859

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 538 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07476859
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07476859. Randomized; no masking; primary purpose treatment. Start 2026-03-05 (actual); primary completion 2028-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome
Acronym
HI-COR-65
Condition
Acute Coronary Syndromes (ACS)
Condition
Iron Deficiencies
Condition
Elderly (People Aged 65 or More)
Intervention (Drug)
Ferric Carboxymaltose Injection [Ferinject]
Lead sponsor
Fundación para la Investigación del Hospital Clínico de Valencia (class: other)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct07476859
Content hash
fe829d6dd7209b2acc7a89d264f3f65122905b222fb2f5ee8b9f1185ebe65374